FDA investigating Matria Healthcare, other firms, for subcutaneous infusion of terbutaline.
This article was originally published in The Gray Sheet
Executive Summary
FDA INVESTIGATING TERBUTALINE DELIVERY VIA INFUSION PUMPS BY MATRIA, OTHER FIRMS, the agency notes in its response to a National Women's Health Network's petition to enjoin Matria Healthcare from marketing and distributing subcutaneous infusion pumps for the management of preterm labor. The agency reports that it is "investigating the activities of Matria and other providers of home health care services" with respect to their promoting terbutaline for preventing preterm labor.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.